Prognosis of Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization(MC-hccAI 001): Development and Validation of the ALFP Score

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73(Suppl 1):4–13. doi:10.1002/hep.31288
   PubMed Web of Science ®Google Scholar
• Kim DW, Talati C, Kim R. Hepatocellular carcinoma (HCC): beyond sorafenib-chemotherapy. J Gastrointest Oncol. 2017;8(2):256–265. doi:10.21037/jgo.2016.09.07
   PubMed Web of Science ®Google Scholar
• Hucke F, Sieghart W, Schöniger-Hekele M, Peck-Radosavljevic M, Müller C. Clinical characteristics of patients with hepatocellular carcinoma in Austria - is there a need for a structured screening program? Wien Klin Wochenschr. 2011;123(17–18):542–551. doi:10.1007/s00508-011-0033-9
   PubMed Web of Science ®Google Scholar
• Llovet JM, Real MI, Montaña X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359(9319):1734–1739. doi:10.1016/S0140-6736(02)08649-X
   PubMed Web of Science ®Google Scholar
• Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–693. doi:10.1016/j.jhep.2021.11.018
   PubMed Web of Science ®Google Scholar
• Bolondi L, Burroughs A, Dufour JF, et al. Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis. 2012;32(4):348–359. doi:10.1055/s-0032-1329906
   PubMed Web of Science ®Google Scholar
• Raoul JL, Sangro B, Forner A, et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev. 2011;37(3):212–220. doi:10.1016/j.ctrv.2010.07.006
   PubMed Web of Science ®Google Scholar
• Burrel M, Reig M, Forner A, et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using drug eluting beads. Implications for clinical practice and trial design. J Hepatol. 2012;56(6):212–220. doi:10.1016/j.jhep.2012.01.008
   Web of Science ®Google Scholar
• Malagari K, Pomoni M, Moschouris H, et al. Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis. Cardiovasc Intervent Radiol. 2012;35(5):1119–1128. doi:10.1007/s00270-012-0394-0
   PubMed Web of Science ®Google Scholar
• Woreta TA, Alqahtani SA. Evaluation of abnormal liver tests. Med Clin North Am. 2014;98(1):1–16. doi:10.1016/j.mcna.2013.09.005
   PubMed Web of Science ®Google Scholar
• Dorgalaleh A, Favaloro EJ, Bahraini M, Rad F. Standardization of Prothrombin Time/International Normalized Ratio (PT/INR). Int J Lab Hematol. 2021;43(1):21–28. doi:10.1111/ijlh.13349
   PubMed Web of Science ®Google Scholar
• Zhang D, Liu Z, Yin X, et al. Prognostic value of PIVKA-II in hepatocellular carcinoma patients receiving curative ablation: a systematic review and meta-analysis. Int J Biol Markers. 2018;33(3):266–274. doi:10.1177/1724600818760234
   PubMed Web of Science ®Google Scholar
• Feng H, Li B, Li Z, Wei Q, Ren L. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma. BMC Cancer. 2021;21(1):401. doi:10.1186/s12885-021-08138-3
   PubMed Web of Science ®Google Scholar
• Wang HS, Ge XX, Li QP, Nie JJ, Miao L. Clinical significance of prothrombin time in cholangiocarcinoma patients with surgeries. Can J Gastroenterol Hepatol. 2019;2019:3413969.
   PubMed Web of Science ®Google Scholar
• Yokoyama Y, Ebata T, Igami T, Sugawara G, Ando M, Nagino M. Predictive power of prothrombin time and serum total bilirubin for postoperative mortality after major hepatectomy with extrahepatic bile duct resection. Surgery. 2014;155(3):504–511. doi:10.1016/j.surg.2013.08.022
   PubMed Web of Science ®Google Scholar
• Furuyama T, Kudo A, Matsumura S, et al. Preoperative direct bilirubin to prothrombin time ratio index to prevent liver failure after minor hepatectomy. J Hepatobiliary Pancreat Sci. 2016;23(12):763–770. doi:10.1002/jhbp.400
   PubMed Web of Science ®Google Scholar
• Mao M, Wang X, Song Y, et al. Novel prognostic scores based on plasma prothrombin time and fibrinogen levels in patients with AFP-negative Hepatocellular Carcinoma. Cancer Control. 2020;27(1):1073274820915520. doi:10.1177/1073274820915520
   Web of Science ®Google Scholar
• Haruki K, Shiba H, Saito N, et al. Risk stratification using a novel liver functional reserve score of combination prothrombin time-international normalized ratio to albumin ratio and albumin in patients with hepatocellular carcinoma. Surgery. 2018;164(3):404–410. doi:10.1016/j.surg.2018.02.022
   PubMed Web of Science ®Google Scholar
• Shen L, Zeng Q, Guo P, et al. Dynamically prognosticating patients with hepatocellular carcinoma through survival paths mapping based on time-series data. Nat Commun. 2018;9(1):2230. doi:10.1038/s41467-018-04633-7
   PubMedGoogle Scholar
• Chen MS, Li JQ, Zhang YQ, et al. High-dose iodized oil transcatheter arterial chemoembolization for patients with large hepatocellular carcinoma. World J Gastroenterol. 2002;8(1):74–78. doi:10.3748/wjg.v8.i1.74
   PubMed Web of Science ®Google Scholar
• Chen ZH, Hong YF, Lin J, et al. Validation and ranking of seven staging systems of hepatocellular carcinoma. Oncol Lett. 2017;14(1):705–714. doi:10.3892/ol.2017.6222
   PubMed Web of Science ®Google Scholar
• He C, Zhang Y, Lin X. Increased overall survival and decreased cancer-specific mortality in patients with hepatocellular carcinoma treated by transarterial chemoembolization and human adenovirus type-5 combination therapy: a competing risk analysis. J Gastrointest Surg. 2018;22(6):989–997. doi:10.1007/s11605-018-3703-3
   PubMed Web of Science ®Google Scholar
• Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33(6):550–558. doi:10.1200/JCO.2014.57.9151
   PubMed Web of Science ®Google Scholar
• Mehta N, Bhangui P, Yao FY, et al. Liver transplantation for hepatocellular carcinoma. Working Group report from the ILTS transplant oncology consensus conference. Transplantation. 2020;104(6):1136–1142. doi:10.1097/TP.0000000000003174
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693–699. doi:10.1056/NEJM199603143341104
   PubMed Web of Science ®Google Scholar
• Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35(5):1164–1171. doi:10.1053/jhep.2002.33156
   PubMed Web of Science ®Google Scholar
• The Cancer of the Liver Italian Program (CLIP) Investigators. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology. 2000;31(4):840–845. doi:10.1053/he.2000.5628
   PubMed Web of Science ®Google Scholar
• Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol. 2003;38(3):207–215. doi:10.1007/s005350300038
   PubMed Web of Science ®Google Scholar
• Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19(3):329–338. doi:10.1055/s-2007-1007122
   PubMed Web of Science ®Google Scholar
• Durand F, Valla D. Assessment of prognosis of cirrhosis. Semin Liver Dis. 2008;28(1):110–122. doi:10.1055/s-2008-1040325
   PubMed Web of Science ®Google Scholar
• Hickey R, Mouli S, Kulik L, et al. Independent analysis of albumin-bilirubin grade in a 765-patient cohort treated with transarterial locoregional therapy for Hepatocellular Carcinoma. J Vasc Interv Radiol. 2016;27(6):795–802. doi:10.1016/j.jvir.2016.03.005
   PubMed Web of Science ®Google Scholar
• Li MX, Zhao H, Bi XY, et al. Prognostic value of the albumin-bilirubin grade in patients with hepatocellular carcinoma: validation in a Chinese cohort. Hepatol Res. 2017;47(8):731–741. doi:10.1111/hepr.12796
   PubMed Web of Science ®Google Scholar
• Ma XL, Zhou JY, Gao XH, et al. Application of the albumin-bilirubin grade for predicting prognosis after curative resection of patients with early-stage hepatocellular carcinoma. Clin Chim Acta. 2016;462:15–22. doi:10.1016/j.cca.2016.08.005
   PubMed Web of Science ®Google Scholar
• Pinato DJ, Sharma R, Allara E, et al. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. J Hepatol. 2017;66(2):338–346. doi:10.1016/j.jhep.2016.09.008
   PubMed Web of Science ®Google Scholar
• Ho SY, Liu PH, Hsu CY, et al. Comparison of twelve liver functional reserve models for outcome prediction in patients with hepatocellular carcinoma undergoing surgical resection. Sci Rep. 2018;8(1):4773. doi:10.1038/s41598-018-22923-4
   PubMedGoogle Scholar
• Mizejewski GJ. Biological role of alpha-fetoprotein in cancer: prospects for anticancer therapy. Expert Rev Anticancer Ther. 2002;2(6):709–735. doi:10.1586/14737140.2.6.709
   PubMedGoogle Scholar
• Sauzay C, Petit A, Bourgeois AM, et al. Alpha-foetoprotein (AFP): a multi-purpose marker in hepatocellular carcinoma. Clin Chim Acta. 2016;463:39–44. doi:10.1016/j.cca.2016.10.006
   PubMed Web of Science ®Google Scholar
• Kamei S, Kono K, Amemiya H, et al. Evaluation of VEGF and VEGF-C expression in gastric cancer cells producing alpha-fetoprotein. J Gastroenterol. 2003;38(6):540–547. doi:10.1007/s00535-002-1099-y
   PubMed Web of Science ®Google Scholar
• Sergio A, Cristofori C, Cardin R, et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol. 2008;103(4):914–921. doi:10.1111/j.1572-0241.2007.01712.x
   PubMed Web of Science ®Google Scholar
• Liebman HA, Furie BC, Tong MJ, et al. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med. 1984;310(22):1427–1431. doi:10.1056/NEJM198405313102204
   PubMed Web of Science ®Google Scholar
• Nakao A, Virji A, Iwaki Y, Carr B, Iwatsuki S, Starzl E. Abnormal prothrombin (DES-gamma-carboxy prothrombin) in hepatocellular carcinoma. Hepatogastroenterology. 1991;38(5):450–453.
   PubMed Web of Science ®Google Scholar
• Notarpaolo A, Layese R, Magistri P, et al. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC. J Hepatol. 2017;66(3):552–559. doi:10.1016/j.jhep.2016.10.038
   PubMed Web of Science ®Google Scholar
• Hiraoka A, Kumada T, Kudo M, et al. Albumin-Bilirubin (ALBI) grade as part of the evidence-based clinical practice guideline for HCC of the Japan Society of Hepatology: a comparison with the liver damage and child-Pugh classifications. Liver Cancer. 2017;6(3):204–215. doi:10.1159/000452846
   PubMed Web of Science ®Google Scholar
• Campani C, Bamba-Funck J, Campion B, et al. Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab-bevacizumab. Liver Int. 2023;43(3):708–717. doi:10.1111/liv.15487
   PubMed Web of Science ®Google Scholar